Medtronic's "Best Growth in a Decade" Was Mostly Currency, and Constant-Currency EPS Fell 2%

---

There is a particular kind of corporate good news that is best understood by what it chooses to put in the headline and what it leaves for the footnotes. Medtronic's fiscal 2026 results, reported June 3, 2026, are a master class in the form. The press release headline read: "delivers highest annual revenue growth in 10 years." That is accurate. Reported revenue rose 8.4% to $36.364 billion, and in the fourth quarter it rose 9.9% to $9.807 billion. For a company that spent the better part of a decade as a byword for medtech stagnation — a sprawling, low-growth conglomerate that serial activists and frustrated holders had pushed to break up — the number reads like a turnaround finally arriving.

Read the same release for thirty seconds longer, though, and the turnaround starts to dissolve into the things that produced it. The 8.4% reported figure became 5.8% once you remove a favorable currency swing. The fourth quarter's 9.9% became 6.6% organic on $308 million of FX help. And on the part of the income statement that pays for dividends and buybacks, the adjusted earnings the company headlines grew six-tenths of one percent for the year — and on a constant-currency basis, the company's own disclosure says, they declined 2%. This is a forensic walk through what is actually growing at Medtronic, what is borrowed from currency and accounting choices, and why a stock priced like a dependable mid-single-digit compounder may be priced for a body of earnings power that, scrubbed clean, is barely growing at all.

The currency that did the heavy lifting

Start with the gap between reported and organic, because it is the difference between the headline and the business. Medtronic reported 8.4% revenue growth for fiscal 2026. Its own reconciliation attributes $824 million of full-year revenue to favorable foreign exchange. Back that out and organic growth was 5.8%. In the fourth quarter the split was even starker relative to the headline: 9.9% reported, 6.6% organic, with $308 million of FX tailwind doing the rest. Currency is not earned; it is weather. A weaker dollar lifts the translated value of European and Asian sales without a single additional device leaving a warehouse, and a stronger dollar takes it all back. Medtronic, which books a large share of revenue outside the United States, is unusually exposed to this weather, and in fiscal 2026 the weather blew its way.

The reason this matters is that "highest growth in ten years" is a frame designed to be remembered, and a 5.8% organic rate is a frame designed to be forgotten. A buyer of the stock at a premium multiple is paying for durable, repeatable expansion. Currency is the opposite of durable: it is mean-reverting and outside management's control. When a company leads with the reported number in the headline and discloses the organic number in the body, it is telling you which version it would like you to anchor on. The honest version of the fiscal 2026 story is not "best growth in a decade." It is "mid-single-digit organic growth, flattered to high-single-digit by a tailwind that will not recur on command."

Constant currency, where the earnings actually shrank

Now follow the same logic down to the bottom line, where it does real damage. Medtronic's non-GAAP — adjusted — diluted EPS for fiscal 2026 was $5.53, up 0.7% from the prior year. That is already a thin number for a company carrying a turnaround narrative: less than one percent of growth in the metric the company itself promotes. But the company's own disclosure goes further. Of that $5.53, roughly $0.15 came from favorable foreign currency. On a constant-currency basis, Medtronic states, adjusted diluted EPS decreased 2.0%.

Sit with that. The largest pure-play device maker in the world, in the year it told investors was its best in a decade, earned less per share in real operating terms than it did the year before. The growth in the headline EPS figure was not operating progress; it was the same currency tailwind that flattered the top line, working a second time on the bottom. A company whose constant-currency earnings are shrinking is not a compounder having a great year. It is a mature, scale-constrained business whose underlying earnings power is flat-to-down, wearing a good year's clothing borrowed from the dollar.

The dollar-eighty between GAAP and "adjusted"

There is a second accounting wedge, and it is wider than the currency one. Medtronic's GAAP diluted EPS for fiscal 2026 — the figure computed under generally accepted accounting principles, the one an auditor signs — was $3.73. The adjusted figure the company leads with was $5.53. The difference is $1.80 per share, or roughly a third of the adjusted number, that exists only because management excluded it.

Adjustments are not inherently sinister; restructuring charges, acquisition amortization, and certain litigation items can genuinely obscure underlying performance, and every large medtech company reports a non-GAAP figure. But the size and the persistence are the tell. When the "one-time" and "non-recurring" exclusions add up to a third of stated earnings year after year, they stop being noise and start being the cost of running the business. Medtronic's full-year GAAP operating margin was 17.8%; its adjusted operating margin was 24.4% — a 6.6-point spread between the profitability the accounting standards recognize and the profitability the slide deck features. And note the direction of the adjusted figure even on its own generous terms: adjusted operating margin fell about 130 basis points year over year. The premium narrative rests on the 24.4% number. The company that pays taxes and reports to the SEC lives closer to the 17.8% one, and even the flattering version is contracting.

The spin that didn't subtract the growth

The most elegant piece of financial engineering in the fiscal 2026 story is the one that was supposed to fix the growth problem and instead illustrates it. For years, Medtronic's diabetes unit — now branded MiniMed — was the drag everyone pointed to: a chronically underperforming business that lost insulin-pump share after an FDA warning letter and held back the consolidated growth rate. The fix, announced and then executed, was to separate it. On March 9, 2026, MiniMed completed an initial public offering, raising roughly $538 million and beginning to trade on the Nasdaq.

Here is the sleight of hand worth naming. The IPO floated only about 10% of MiniMed. Medtronic disclosed that, following the offering, it still owns approximately 90.03% of the outstanding common stock. Under consolidation accounting, a 90%-owned subsidiary's revenue still flows into the parent's reported and organic growth. So in the very fiscal year Medtronic celebrated its best growth in a decade, the diabetes business it had spent years framing as separable was still inside the numbers — and it was growing. Diabetes revenue was $3.112 billion, up about 7.9% organically, one of the faster-growing pieces of the company. The unit that was the drag had become a contributor, and the spin that was meant to remove it had removed almost none of it.

This is the denominator illusion in reverse. The standard breakup logic is: cut out the slow part, and the remaining company's growth rate looks better. Medtronic's actual fiscal 2026 logic was: keep 90% of the now-faster part inside the consolidation, harvest its growth in the headline, and book the optics of "separation" at the same time. When the remaining stake is eventually distributed or sold, that ~8% grower exits the organic rate — and what is left is the slower core. The market is currently being shown the version with diabetes still in it.

The two segments running on fumes

Pull the segment detail and the "best in a decade" story narrows to one engine. Of Medtronic's four reporting segments in fiscal 2026, only Cardiovascular grew at a genuinely robust clip — revenue of $13.976 billion, up 9.3% organically, carried by structural heart, cardiac ablation, and the Hugo surgical-robotics and pulsed-field-ablation stories the bulls love. Diabetes, as noted, grew about 7.9%. But the other two segments — nearly half the company — barely moved. Neuroscience, at $10.287 billion, grew 3.1% organically. Medical Surgical, at $8.815 billion, grew 2.9%.

So the consolidated 5.8% organic figure is an average of one strong segment, one rehabilitated mid-grower, and two large franchises growing at roughly the rate of the economy. That is not the profile of a company that has solved its growth problem; it is the profile of a company with one good horse pulling a heavy cart. If Cardiovascular's momentum normalizes — and structural-heart and ablation markets are competitive, with Boston Scientific and Abbott pressing hard — the blended rate has very little underneath it. The premium narrative implicitly assumes Cardiovascular stays hot and the laggards inflect. The fiscal 2026 numbers show only the first half of that assumption being met.

A denominator of 1.29 billion shares

Every per-share figure Medtronic reports is divided by an enormous number. Diluted weighted-average shares outstanding for fiscal 2026 were 1,288.1 million — roughly 1.29 billion shares. That heft is the quiet reason the turnaround in absolute dollars never quite shows up per share. Reported net income can rise, segments can grow, and the EPS line still barely moves because it is spread across one of the largest share counts in medtech.

It also caps the buyback's power. Medtronic returned about $4.2 billion to shareholders in fiscal 2026 between dividends and repurchases, and it proudly raised the dividend for a 49th consecutive year to a $2.88 annualized rate. The dividend is real and the streak is admirable. But against a 1.29-billion-share base and a roughly $102 billion market capitalization, buybacks move the share count at the margin, not in a way that manufactures meaningful EPS growth. The company cannot shrink its way to a higher per-share number fast enough to offset flat constant-currency operating earnings. The denominator is simply too large, and it is one more reason the headline dollars and the per-share reality keep diverging.

Priced like a compounder, growing like a utility

Put the valuation against the cleaned-up growth. At roughly $79 per share in early June 2026, Medtronic carried a market capitalization near $102 billion, a trailing P/E around 21, and a forward P/E around 12 — the forward multiple implying the market expects the adjusted-EPS line to step up materially. For fiscal 2027, management guided to organic revenue growth of 6.75% to 7.25% and adjusted EPS of $5.90 to $6.00. Read the fine print on that guidance and some of the lift is, again, mechanical: the company flagged roughly 125 basis points of the organic guide coming from an extra selling week in the fiscal calendar, and about 25 basis points from the diabetes business. Back out the extra week and the underlying organic guide is closer to the high fives — right where fiscal 2026 actually landed once currency was stripped.

The asymmetry is the point. A forward multiple in the low teens is not, in isolation, demanding for a healthcare staple. But it is being paid for a forward EPS number that leans on a 53rd week, a currency assumption that is neutral-to-helpful only if the dollar cooperates, and a Cardiovascular engine that has to keep outrunning entrenched competitors while the other half of the company idles at 3%. If currency turns into a headwind, if the extra week's benefit is correctly seen as non-recurring, or if Cardiovascular cools, the constant-currency reality — flat-to-down operating earnings — is what investors are left holding. That is priced-for-perfection asymmetry dressed in a value multiple: limited upside if everything breaks right, real downside if the borrowed tailwinds reverse.

Quality of earnings, line by line

One more pass through the quality of what was reported. Operating cash flow for fiscal 2026 was $7.330 billion, up 4.1%, and free cash flow was $5.426 billion, up 4.6% — both growing, but both growing slower than the 8.4% reported revenue headline, which is itself a quiet confirmation that the top-line number was flattered relative to the cash the business actually threw off. Conversion of net income to cash is solid, as you would expect from a scaled device maker, but the growth rates tell you the cash engine is expanding at low-single-digit speed, not the high-single-digit speed of the headline.

Layer in the MiniMed-related charges that forced a guidance cut earlier in the year — Medtronic trimmed its fiscal 2026 adjusted-EPS outlook after disclosing a one-time charge tied to a future Blackstone payment connected to the diabetes unit, a charge that flows to Medtronic precisely because it still owns ~90% of MiniMed. The separation that was sold as clean addition-by-subtraction is generating its own liabilities that land back on the parent. Each of these items is individually defensible and individually disclosed. Stacked together — currency-flattered revenue, currency-flattered and constant-currency-negative EPS, a $1.80 GAAP-to-adjusted wedge, a contracting adjusted margin, a still-consolidated "spun" unit, and cash flow growing at a third of the headline rate — they describe a company whose reported strength is substantially manufactured by the items management asks you to look past.

What the bulls genuinely get right

The bear case here is about framing, not about a broken company, and intellectual honesty requires conceding how much the bulls get right — because it is a great deal. Medtronic is, by revenue, the largest pure-play medical-device company in the world, with a portfolio spanning cardiac, neurological, surgical, and diabetes care that is genuinely diversified, genuinely defensive, and genuinely hard to replicate. Its Cardiovascular segment is not a mirage: 9.3% organic growth on nearly $14 billion of revenue is excellent, and the pipeline behind it — pulsed-field ablation, structural heart, and the Hugo robotic-surgery platform — addresses large markets where Medtronic has real clinical and commercial advantages. Robotics in particular could be a multiyear growth driver that the current valuation barely credits.

The diabetes turnaround is real too. The business that was the company's albatross returned to roughly 8% organic growth, won fresh insulin-pump clearances, and is being positioned with new product launches and outside capital from Blackstone. The dividend deserves its respect: a 49th consecutive annual increase is an elite track record of capital return that very few companies anywhere can claim, and it signals balance-sheet durability and management discipline. Free cash flow of $5.4 billion comfortably funds it. And the valuation itself is the bulls' strongest card — a forward P/E around 12 with a dividend yield near 3.5% is not the setup of an obviously overpriced stock; it is a price at which modest, mid-single-digit organic growth plus the yield can produce a perfectly respectable total return without anything heroic happening. If currency stays neutral, Cardiovascular stays hot, and the laggard segments merely hold, the stock can work from here. The bears' job is not to deny any of this. It is to insist that the "best growth in a decade" headline is doing more narrative work than the underlying, currency-scrubbed, constant-currency numbers can support — and that a buyer should pay the value-stock multiple for the value-stock growth rate, not the compounder multiple for a compounder that exists mostly in the reported, FX-flattered version of the year.

The kicker

So which Medtronic is the real one — the company that delivered its best growth in ten years, or the company whose constant-currency earnings fell 2%? They are the same company, and that is exactly the problem. The headline and the footnote describe one business, and the only difference between them is a favorable dollar, a third of earnings excluded as "adjustments," an extra week on the calendar, and a diabetes unit that was "spun off" while staying 90% owned. None of those are growth. They are the costume growth wears in a good year for the currency. Strip the costume and you find a magnificent, durable, diversified device maker growing in the low-to-mid single digits and paying a fine dividend — a fact that is perfectly investable at the right price, and dangerously easy to overpay for at the wrong one, because the company keeps handing you the number that makes the overpayment feel justified.

The most honest line in the entire fiscal 2026 release is the one no headline quoted: on a constant-currency basis, adjusted earnings per share decreased two percent — and everything bullish about Medtronic depends on you reading the other sentence first.